The global epigenetics market is projected to reach USD 3.9 Billion by 2027 from USD 1.7 Billion in 2022, at a CAGR of 18.1% during the forecast period. Significant reduction in the sequencing associated costs is among the key driving factors of the epigenetics market. Advent of affordable NGS systems along with the decline in cost of genome sequencing services boosts the epigenetics sequencing, further driving the market growth. Illumina, Inc. (US) has introduced various affordable NGS solutions over the years, post the launch of its iSeq benchtop sequencer in 2018. Additionally, declining costs have also rendered targeted bisulphite sequencing a feasible option, in turn driving the market growth.
Epigenetics market is moderately consolidated and competitive in nature, market players are adopting different strategies to sustain market competition. Prominent players have introduced cutting-edge solutions for epigenetic sequencing and epigenetic analysis to sustain the industry competition. Most prominent players have built a diverse portfolio of kits, reagents, and consumables to cater to customer needs. Prominent players in the global epigenetics market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories (US), Promega Corporation (US), PerkinElmer (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode (Germany), and F. Hoffmann-La Roche Ltd (Switzerland).
To know about the assumptions considered for the study download the pdf brochure
ILLUMINA, INC. (US)
Illumina, Inc. (US) accounted for the largest share in the epigenetics market in 2021. Illumina, Inc. is one of the prominent companies engaged in developing array-based solutions and sequencing products targeted towards genetic applications. The company has been able to build a strong customer base, which spans across pharmaceutical & biotechnology companies, genomic research centers, and government laboratories & hospitals. Additionally, Illumina exhibits monopoly in the NGS market, which offers the company a competitive edge to enter the adjacent markets like epigenetic sequencing.
THERMO FISHER SCIENTIFIC (US)
Thermo Fisher Scientific (US) ranked second in the epigenetics market in 2021. Strong brand image of the company along with the diverse product portfolio is attributive to the company’s share in the epigenetics market. Life Science has been a strong source of revenue stream for Thermo Fisher Scientific through 2019 to 2021, the company offers epigenetics solutions through its Life Science business segment. The acquisition of Life Technologies allowed it to develop advanced solutions for functional analysis assays, sample preparation, sequencing, and quantitative PCR (qPCR). Its diverse offers have strengthened its presence in epigenetics research.
MERCK KGaA (GERMANY)
Merck KGaA (Germany) accounted for the third-largest share in the epigenetics market revenue in 2021. The company offers an array of epigenetics assays and kits through the Life Science Research business segment, which accounted for more than 45% of the company’s revenue generated in 2021. Merck has developed several assays to effectively evaluate DNA methylation within the entire genome or at a single locus. Merck has a strong presence in the consumables sector; its offerings include antibodies, kits, and reagents.
Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Software, Service), Method (DNA Methylation), Technique (NGS, PCR & qPCR), Application (Oncology, Immunology), End User - Global Forecast to 2027
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE